{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:49:22Z","timestamp":1795024162521,"version":"4.10.2"},"reference-count":217,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.biopha.2025.118007","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T11:51:27Z","timestamp":1745236287000},"page":"118007","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Antibiotic conjugates: Using molecular Trojan Horses to overcome drug resistance"],"prefix":"10.1016","volume":"186","author":[{"given":"Xi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2962-4086","authenticated-orcid":false,"given":"Yijie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118007_bib1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.11622\/smedj.2015105","article-title":"Alexander Fleming (1881-1955): discoverer of penicillin","volume":"56","author":"Tan","year":"2015","journal-title":"Singap. Med. J."},{"key":"10.1016\/j.biopha.2025.118007_bib2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ijantimicag.2018.11.010","article-title":"Antibiotic discovery: history, methods, and perspectives","volume":"53","author":"Durand","year":"2019","journal-title":"Int J. Antimicrob. Agents"},{"key":"10.1016\/j.biopha.2025.118007_bib3","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3201\/eid2305.161556","article-title":"The discovery of penicillin-new insights after more than 75 years of clinical use","volume":"23","author":"Gaynes","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.biopha.2025.118007_bib4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3181\/00379727-55-14461","article-title":"Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria. Proceedings of the Society for","volume":"55","author":"Schatz","year":"1944","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.biopha.2025.118007_bib5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1749-6632.1948.tb27262.x","article-title":"Aureomycin: a product of the continuing search for new antibiotics","volume":"51","author":"Duggar","year":"1948","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.biopha.2025.118007_bib6","first-page":"281","article-title":"\"llotycin,\" a new antibiotic","volume":"2","author":"McGuire","year":"1952","journal-title":"Antibiot. Chemother."},{"key":"10.1016\/j.biopha.2025.118007_bib7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1021\/jm00340a034","article-title":"Gentamicin, a new antibiotic complex from Micromonospora","volume":"6","author":"Weinstein","year":"1963","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118007_bib8","doi-asserted-by":"crossref","first-page":"18033","DOI":"10.1038\/nrdp.2018.33","article-title":"Methicillin-resistant Staphylococcus aureus","volume":"4","author":"Lee","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"6435","key":"10.1016\/j.biopha.2025.118007_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau4679","article-title":"The challenge of antimicrobial resistance: what economics can contribute","volume":"364","author":"Roope","year":"2019","journal-title":"Science"},{"issue":"10325","key":"10.1016\/j.biopha.2025.118007_bib10","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118007_bib11","unstructured":"GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204\u20131222. Erratum in: Lancet. 2020;396(10262):1562. ."},{"key":"10.1016\/j.biopha.2025.118007_bib12","unstructured":"GLASS | Global Antimicrobial Resistance Surveillance System (GLASS). WHO 2020."},{"key":"10.1016\/j.biopha.2025.118007_bib13","first-page":"84","volume":"1","author":"O'Neil","year":"2016"},{"key":"10.1016\/j.biopha.2025.118007_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41579-024-01054-w","article-title":"ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics","author":"Miller","year":"2024","journal-title":"Nat. Rev. Microbiol"},{"key":"10.1016\/j.biopha.2025.118007_bib15","unstructured":"WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance (\u3008https:\/\/www.who.int\/publications\/i\/item\/9789240093461\u3009)."},{"key":"10.1016\/j.biopha.2025.118007_bib16","first-page":"46","article-title":"Action and resistance mechanisms of antibiotics: a guide for clinicians","volume":"34","author":"Garima","year":"2018","journal-title":"J. Anaesthesiol. Clin. Pharm."},{"issue":"12","key":"10.1016\/j.biopha.2025.118007_bib17","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.jiph.2021.10.020","article-title":"Antibiotic resistance in microbes: history, mechanisms, therapeutic strategies and future prospects","volume":"14","author":"Uddin","year":"2021","journal-title":"J. Infect. Public Health"},{"issue":"6","key":"10.1016\/j.biopha.2025.118007_bib18","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3390\/molecules25061340","article-title":"Resistance of Gram-negative bacteria to current antibacterial agents and approaches to resolve it","volume":"25","author":"Breijyeh","year":"2020","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.biopha.2025.118007_bib19","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1128\/AAC.49.4.1432-1440.2005","article-title":"Acquisition of resistance to carbapenems in multidrug-resistant clinical strains of Acinetobacter baumannii: natural insertional inactivation of a gene encoding a member of a novel family of beta-barrel outer membrane proteins","volume":"49","author":"Mussi","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2025.118007_bib20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.nmni.2017.10.013","article-title":"Insertional inactivation of oprD in carbapenem-resistant Pseudomonas aeruginosa strains isolated from burn patients in Tehran, Iran","volume":"21","author":"Shariati","year":"2017","journal-title":"N. Microbes N. Infect."},{"issue":"1","key":"10.1016\/j.biopha.2025.118007_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13756-019-0533-3","article-title":"Antibiotics versus biofilm: an emerging battleground in microbial communities","volume":"8","author":"Sharma","year":"2019","journal-title":"Antimicrob. Resist Infect. Control"},{"key":"10.1016\/j.biopha.2025.118007_bib22","article-title":"Relationship between biofilm formation and antibiotic resistance of Klebsiella pneumoniae and updates on antibiofilm therapeutic strategies","volume":"14","author":"Li","year":"2024","journal-title":"Front Cell Infect. Microbiol"},{"issue":"5","key":"10.1016\/j.biopha.2025.118007_bib23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.12968\/jowc.2018.27.5.273","article-title":"Antibiotic resistance and biofilm tolerance: a combined threat in the treatment of chronic infections","volume":"27","author":"Bowler","year":"2018","journal-title":"J. Wound Care"},{"issue":"7","key":"10.1016\/j.biopha.2025.118007_bib24","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3390\/antibiotics10070774","article-title":"Ever-adapting RND efflux pumps in Gram-negative multidrug-resistant pathogens: a race against time","volume":"10","author":"Zwama","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.biopha.2025.118007_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2016.04.003","article-title":"Multidrug efflux pumps of Gram-positive bacteria","volume":"27","author":"Schindler","year":"2016","journal-title":"Drug Resist Updat"},{"issue":"12","key":"10.1016\/j.biopha.2025.118007_bib26","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1093\/jac\/dkt286","article-title":"Association of norB overexpression and fluoroquinolone resistance in clinical isolates of Staphylococcus aureus from Korea","volume":"68","author":"Kwak","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.biopha.2025.118007_bib27","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a025247","article-title":"\u03b2-lactams and \u03b2-lactamase inhibitors: an overview","volume":"6","author":"Bush","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118007_bib28","doi-asserted-by":"crossref","first-page":"a025239","DOI":"10.1101\/cshperspect.a025239","article-title":"\u03b2-Lactamases: a focus on current challenges","volume":"7","author":"Bonomo","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"3","key":"10.1016\/j.biopha.2025.118007_bib29","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s40121-023-00771-8","article-title":"\u03b2-lactam resistance in ESKAPE pathogens mediated through modifications in penicillin-binding proteins: an overview","volume":"12","author":"Sethuvel","year":"2023","journal-title":"Infect. Dis. Ther."},{"issue":"12","key":"10.1016\/j.biopha.2025.118007_bib30","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1128\/JB.01520-09","article-title":"Roles of CcrA and CcrB in excision and integration of staphylococcal cassette chromosome mec, a Staphylococcus aureus genomic island","volume":"192","author":"Wang","year":"2010","journal-title":"J. Bacteriol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118007_bib31","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1469-0691.2010.03226.x","article-title":"Mobile genetic elements and their contribution to the emergence of antimicrobial resistant Enterococcus faecalis and Enterococcus faecium","volume":"16","author":"Hegstad","year":"2010","journal-title":"Clin. Microbiol Infect."},{"issue":"2","key":"10.1016\/j.biopha.2025.118007_bib32","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3390\/antibiotics11020200","article-title":"Progress in alternative strategies to combat antimicrobial resistance: focus on antibiotics","volume":"11","author":"Murugaiyan","year":"2022","journal-title":"Antibiotics"},{"issue":"2","key":"10.1016\/j.biopha.2025.118007_bib33","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.molmed.2016.12.008","article-title":"Antibody-antibiotic conjugates: a novel therapeutic platform against bacterial infections","volume":"23","author":"Mariathasan","year":"2017","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.biopha.2025.118007_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.835677","article-title":"The use of antibody-antibiotic conjugates to fight bacterial infections","volume":"13","author":"Cavaco","year":"2022","journal-title":"Front. Microbiol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118007_bib35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1515\/pac-2018-0707","article-title":"Combating bacterial resistance by combination of antibiotics with antimicrobial peptides","volume":"91","author":"Sheard","year":"2019","journal-title":"Pure Appl. Chem."},{"key":"10.1016\/j.biopha.2025.118007_bib36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10989-023-10561-y","article-title":"Antibiotic-peptide conjugation against multi-drug resistant pathogens: a comprehensive review for therapeutics and drug delivery strategies","volume":"29","author":"Kalimuthu","year":"2023","journal-title":"Int. J. Pept. Res. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2025.118007_bib37","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1039\/D2MD00465H","article-title":"Siderophore conjugates to combat antibiotic-resistant bacteria","volume":"14","author":"Rayner","year":"2023","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.biopha.2025.118007_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129282","article-title":"Siderophores: chemical tools for precise antibiotic delivery","volume":"87","author":"Rodr\u00edguez","year":"2023","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"18","key":"10.1016\/j.biopha.2025.118007_bib39","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.3390\/molecules24183314","article-title":"Siderophore-antibiotic conjugate design: new drugs for bad bugs?","volume":"24","author":"Negash","year":"2019","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.biopha.2025.118007_bib40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2302\/kjm.60.37","article-title":"Therapeutic monoclonal antibodies","volume":"60","author":"Yamada","year":"2011","journal-title":"Keio J. Med."},{"key":"10.1016\/j.biopha.2025.118007_bib41","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.biopha.2025.118007_bib42","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00397-17","article-title":"A new take on an old remedy: generating antibodies against multidrug-resistant Gram-negative bacteria in a post-antibiotic world","volume":"2","author":"Motley","year":"2017","journal-title":"mSphere"},{"issue":"3","key":"10.1016\/j.biopha.2025.118007_bib43","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/QCO.0000000000000539","article-title":"Monoclonal antibody-based therapies for bacterial infections","volume":"32","author":"Motley","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"issue":"11","key":"10.1016\/j.biopha.2025.118007_bib44","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1007\/s00253-022-11989-w","article-title":"Anti-bacterial monoclonal antibodies: next generation therapy against superbugs","volume":"106","author":"Wang","year":"2022","journal-title":"Appl. Microbiol Biotechnol."},{"issue":"10200","key":"10.1016\/j.biopha.2025.118007_bib45","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.biopha.2025.118007_bib46","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/antib10040042","article-title":"Introduction to antibody-drug conjugates","volume":"10","author":"Pettinato","year":"2021","journal-title":"Antibodies"},{"issue":"25","key":"10.1016\/j.biopha.2025.118007_bib47","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1016\/j.tet.2015.09.069","article-title":"Targeted treatment for bacterial infections: prospects for pathogen-specific antibiotics coupled with rapid diagnostics","volume":"72","author":"Maxson","year":"2016","journal-title":"Tetrahedron"},{"issue":"15","key":"10.1016\/j.biopha.2025.118007_bib48","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1002\/anie.201307628","article-title":"Antibody-drug conjugates: an emerging concept in cancer therapy","volume":"53","author":"Chari","year":"2014","journal-title":"Angew. Chem. Int Ed. Engl."},{"issue":"2","key":"10.1016\/j.biopha.2025.118007_bib49","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41579-019-0310-6","article-title":"New drugs for the antibacterial pipeline?","volume":"18","author":"York","year":"2020","journal-title":"Nat. Rev. Microbiol"},{"key":"10.1016\/j.biopha.2025.118007_bib50","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/jac\/dkv448","article-title":"Extended-spectrum antibodies protective against carbapenemase-producing Enterobacteriaceae","volume":"71","author":"Skurnik","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.biopha.2025.118007_bib51","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.biotechadv.2016.07.004","article-title":"Therapeutic monoclonal antibodies and derivatives: historical perspectives and future directions","volume":"34","author":"Rodgers","year":"2016","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.biopha.2025.118007_bib52","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009655","article-title":"A multifunctional bispecific antibody protects against Pseudomonas aeruginosa","volume":"6","author":"DiGiandomenico","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biopha.2025.118007_bib53","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.sbi.2019.12.001","article-title":"Antibody recognition of bacterial surfaces and extracellular polysaccharides","volume":"62","author":"Soliman","year":"2020","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.biopha.2025.118007_bib54","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4161\/viru.25965","article-title":"Anti-endotoxin vaccines: back to the future","volume":"5","author":"Cross","year":"2014","journal-title":"Virulence"},{"key":"10.1016\/j.biopha.2025.118007_bib55","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s10096-014-2156-1","article-title":"Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia","volume":"33","author":"Que","year":"2014","journal-title":"Eur. J. Clin. Microbiol Infect. Dis."},{"key":"10.1016\/j.biopha.2025.118007_bib56","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00456-16","article-title":"Antibody-based immunotherapy to treat and prevent infection with hypervirulent Klebsiella pneumoniae","volume":"24","author":"Diago-Navarro","year":"2017","journal-title":"Clin. Vaccin. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118007_bib57","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.bjae.2022.01.003","article-title":"Bacterial endotoxins and exotoxins in intensive care medicine","volume":"22","author":"Sheehan","year":"2022","journal-title":"BJA Educ."},{"issue":"1","key":"10.1016\/j.biopha.2025.118007_bib58","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1476-8518-2-5","article-title":"Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed","volume":"2","author":"Sawada-Hirai","year":"2004","journal-title":"J. Immune Based Ther. Vaccin."},{"issue":"2","key":"10.1016\/j.biopha.2025.118007_bib59","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa0810603","article-title":"Raxibacumab for the treatment of inhalational anthrax","volume":"361","author":"Migone","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.biopha.2025.118007_bib60","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40265-016-0577-0","article-title":"Obiltoxaximab: first global approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"issue":"26","key":"10.1016\/j.biopha.2025.118007_bib61","doi-asserted-by":"crossref","first-page":"18008","DOI":"10.1074\/jbc.M114.560748","article-title":"Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography","volume":"289","author":"Orth","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2025.118007_bib62","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nri.2017.106","article-title":"Beyond binding: antibody effector functions in infectious diseases","volume":"18","author":"Lu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118007_bib63","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2025.118007_bib64","article-title":"Antibody-antibiotic conjugates: a comprehensive review on their therapeutic potentials against bacterial infections","volume":"13","author":"Darbandi","year":"2024","journal-title":"J. Clin. Lab Anal."},{"issue":"2","key":"10.1016\/j.biopha.2025.118007_bib65","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/13543776.2017.1259411","article-title":"Trends in therapeutic drug conjugates for bacterial diseases: a patent review","volume":"27","author":"Cal","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"issue":"7578","key":"10.1016\/j.biopha.2025.118007_bib66","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nature16057","article-title":"Novel antibody-antibiotic conjugate eliminates intracellular S. aureus","volume":"527","author":"Lehar","year":"2015","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.biopha.2025.118007_bib67","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrmicro2508","article-title":"Are bloodstream leukocytes Trojan Horses for the metastasis of Staphylococcus aureus?","volume":"9","author":"Thwaites","year":"2011","journal-title":"Nat. Rev. Microbiol"},{"issue":"5","key":"10.1016\/j.biopha.2025.118007_bib68","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.coph.2010.06.006","article-title":"Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus","volume":"10","author":"Nannini","year":"2010","journal-title":"Curr. Opin. Pharm."},{"issue":"4","key":"10.1016\/j.biopha.2025.118007_bib69","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00694-20","article-title":"Recalcitrant Staphylococcus aureus infections: obstacles and solutions","volume":"89","author":"Rowe","year":"2021","journal-title":"Infect. Immun."},{"issue":"4","key":"10.1016\/j.biopha.2025.118007_bib70","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1021\/bc025536j","article-title":"Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity","volume":"13","author":"Dubowchik","year":"2002","journal-title":"Bioconjug Chem."},{"issue":"2","key":"10.1016\/j.biopha.2025.118007_bib71","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/ph11020032","article-title":"Antibody-drug conjugates for cancer therapy: chemistry to clinical implications","volume":"11","author":"Dan","year":"2018","journal-title":"Pharmaceuticals"},{"issue":"10","key":"10.1016\/j.biopha.2025.118007_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224096","article-title":"Sustained activity of novel THIOMAB antibody-antibiotic conjugate against Staphylococcus aureus in a mouse model: longitudinal pharmacodynamic assessment by bioluminescence imaging","volume":"14","author":"Zhou","year":"2019","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.biopha.2025.118007_bib73","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02588-18","article-title":"A phase 1, randomized, single-ascending-dose study to investigate the safety, tolerability, and pharmacokinetics of DSTA4637S, an anti-Staphylococcus aureus THIOMAB antibody-antibiotic conjugate, in healthy volunteers","volume":"63","author":"Peck","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2025.118007_bib74","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/BLO.0b013e3181123d4e","article-title":"Higher risk of failure of methicillin-resistant Staphylococcus aureus prosthetic joint infections","volume":"461","author":"Salgado","year":"2007","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"2","key":"10.1016\/j.biopha.2025.118007_bib75","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1302\/2046-3758.92.BJR-2019-0131.R1","article-title":"Recalcitrant methicillin-resistant Staphylococcus aureus infection of bone cells: intracellular penetration and control strategies","volume":"9","author":"Yu","year":"2020","journal-title":"Bon Res."},{"key":"10.1016\/j.biopha.2025.118007_bib76","article-title":"Antibody-antibiotic conjugate targeted therapy for orthopedic implant-associated intracellular S. aureus infections","author":"Qin","year":"2023","journal-title":"J. Adv. Res"},{"issue":"23","key":"10.1016\/j.biopha.2025.118007_bib77","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202301340","article-title":"Antibody-drug conjugates to treat bacterial biofilms via targeting and extracellular drug release","volume":"10","author":"Tvilum","year":"2023","journal-title":"Adv. Sci."},{"issue":"11","key":"10.1016\/j.biopha.2025.118007_bib78","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1111\/1462-2920.12873","article-title":"Combatting bacterial infections by killing persister cells with mitomycin C","volume":"17","author":"Kwan","year":"2015","journal-title":"Environ. Microbiol"},{"issue":"1-2","key":"10.1016\/j.biopha.2025.118007_bib79","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/cbic.201900378","article-title":"Probing for thiol-mediated uptake into bacteria","volume":"21","author":"Laurent","year":"2020","journal-title":"Chembiochem"},{"key":"10.1016\/j.biopha.2025.118007_bib80","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin. Microbiol Rev."},{"issue":"3","key":"10.1016\/j.biopha.2025.118007_bib81","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00202-21","article-title":"Potent killing of pseudomonas aeruginosa by an antibody-antibiotic conjugate","volume":"12","author":"Kajihara","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.biopha.2025.118007_bib82","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41586-018-0483-6","article-title":"Optimized arylomycins are a new class of Gram-negative antibiotics","volume":"561","author":"Smith","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118007_bib83","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/nchem.2635","article-title":"Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody\u2013drug conjugates","volume":"8","author":"Staben","year":"2016","journal-title":"Nat. Chem."},{"issue":"5","key":"10.1016\/j.biopha.2025.118007_bib84","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.drudis.2019.03.002","article-title":"Where are we with monoclonal antibodies for multidrug-resistant infections?","volume":"24","author":"McConnell","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2025.118007_bib85","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.VMBF-0005-2015","article-title":"Antigenic variation in bacterial pathogens","volume":"4","author":"Palmer","year":"2016","journal-title":"Microbiol Spectr."},{"key":"10.1016\/j.biopha.2025.118007_bib86","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.3389\/fimmu.2020.01938","article-title":"Evolutionary approaches to combat antibiotic resistance: opportunities and challenges for precision medicine","volume":"11","author":"Merker","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2025.118007_bib87","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.3389\/fimmu.2019.02841","article-title":"Using omics technologies and systems biology to identify epitope targets for the development of monoclonal antibodies against antibiotic-resistant bacteria","volume":"10","author":"Mart\u00edn-Galiano","year":"2019","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118007_bib88","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/antib8020036","article-title":"Current advancements in addressing key challenges of therapeutic antibody design, manufacture, and formulation","volume":"8","author":"Sifniotis","year":"2019","journal-title":"antibodies"},{"issue":"2","key":"10.1016\/j.biopha.2025.118007_bib89","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/19420862.2015.1115937","article-title":"Key factors influencing ADME properties of therapeutic proteins: a need for ADME characterization in drug discovery and development","volume":"8","author":"Tibbitts","year":"2016","journal-title":"MAbs"},{"issue":"5","key":"10.1016\/j.biopha.2025.118007_bib90","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1021\/acs.bioconjchem.7b00062","article-title":"Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody-maytansinoid conjugates","volume":"28","author":"Sun","year":"2017","journal-title":"Bioconjug Chem."},{"issue":"11","key":"10.1016\/j.biopha.2025.118007_bib91","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1039\/D1SC05243H","article-title":"A homogeneous high-DAR antibody-drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides","volume":"13","author":"Zacharias","year":"2022","journal-title":"Chem. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2025.118007_bib92","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1089\/mdr.2017.0392","article-title":"Antimicrobial peptides: features, action, and their resistance mechanisms in bacteria","volume":"24","author":"Moravej","year":"2018","journal-title":"Micro Drug Resist"},{"issue":"D1","key":"10.1016\/j.biopha.2025.118007_bib93","doi-asserted-by":"crossref","first-page":"D1087","DOI":"10.1093\/nar\/gkv1278","article-title":"APD3: the antimicrobial peptide database as a tool for research and education","volume":"44","author":"Wang","year":"2016","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.118007_bib94","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2174\/1568026615666150703121700","article-title":"Antimicrobial peptide structure and mechanism of action: a focus on the role of membrane structure","volume":"16","author":"Lee","year":"2016","journal-title":"Curr. Top. Med Chem."},{"issue":"6","key":"10.1016\/j.biopha.2025.118007_bib95","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1586\/14787210.5.6.951","article-title":"Alternative mechanisms of action of cationic antimicrobial peptides on bacteria","volume":"5","author":"Hale","year":"2007","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"10","key":"10.1016\/j.biopha.2025.118007_bib96","doi-asserted-by":"crossref","first-page":"5719","DOI":"10.1128\/AAC.02542-14","article-title":"Synergistic effects of antimicrobial peptides and antibiotics against Clostridium difficile","volume":"58","author":"Nuding","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.biopha.2025.118007_bib97","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1007\/s00253-016-7468-x","article-title":"Organization and function of anionic phospholipids in bacteria","volume":"100","author":"Lin","year":"2016","journal-title":"Appl. Microbiol Biotechnol."},{"issue":"9","key":"10.1016\/j.biopha.2025.118007_bib98","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s11274-020-02907-1","article-title":"Antimicrobial peptide polymers: no escape to ESKAPE pathogens-a review","volume":"36","author":"Mukhopadhyay","year":"2020","journal-title":"World J. Microbiol Biotechnol."},{"key":"10.1016\/j.biopha.2025.118007_bib99","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.3389\/fmicb.2019.02866","article-title":"Mechanisms of action for antimicrobial peptides with antibacterial and antibiofilm functions","volume":"10","author":"Raheem","year":"2019","journal-title":"Front. Microbiol."},{"issue":"19","key":"10.1016\/j.biopha.2025.118007_bib100","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.3390\/ijms20194877","article-title":"Non-Lytic Antibacterial peptides that translocate through bacterial membranes to act on intracellular targets","volume":"20","author":"Cardoso","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2025.118007_bib101","doi-asserted-by":"crossref","first-page":"488","DOI":"10.24272\/j.issn.2095-8137.2019.062","article-title":"Antimicrobial peptides: new hope in the war against multidrug resistance","volume":"40","author":"Mwangi","year":"2019","journal-title":"Zool. Res"},{"key":"10.1016\/j.biopha.2025.118007_bib102","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3389\/fcimb.2016.00194","article-title":"Antimicrobial peptides: an emerging category of therapeutic agents","volume":"6","author":"Mahlapuu","year":"2016","journal-title":"Front. Cell Infect. Microbiol"},{"issue":"9","key":"10.1016\/j.biopha.2025.118007_bib103","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.3390\/ijms25094870","article-title":"Antimicrobial peptides towards clinical application-a long history to be concluded","volume":"25","author":"Cresti","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118007_bib104","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s42770-021-00645-6","article-title":"In vitro activity of the antimicrobial peptides h-Lf1-11, MSI-78, LL-37, fengycin 2B, and magainin-2 against clinically important bacteria","volume":"53","author":"Denardi","year":"2022","journal-title":"Braz. J. Microbiol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118007_bib105","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/toxins12080484","article-title":"Enhanced antimicrobial activity of N-terminal derivatives of a novel Brevinin-1 peptide from the skin secretion of Odorrana schmackeri","volume":"12","author":"Zhou","year":"2020","journal-title":"Toxins"},{"issue":"16","key":"10.1016\/j.biopha.2025.118007_bib106","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1021\/jm050347i","article-title":"Designer antibacterial peptides kill fluoroquinolone-resistant clinical isolates","volume":"48","author":"Otvos","year":"2005","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.biopha.2025.118007_bib107","doi-asserted-by":"crossref","first-page":"6788","DOI":"10.3390\/ijms24076788","article-title":"Intelligent de novo design of novel antimicrobial peptides against antibiotic-resistant bacteria strains","volume":"24","author":"Lin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118007_bib108","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4274\/tjps.galenos.2020.43078","article-title":"WLBU2 antimicrobial peptide as a potential therapeutic for treatment of resistant bacterial infections","volume":"19","author":"Elsalem","year":"2022","journal-title":"Turk. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2025.118007_bib109","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.715246","article-title":"Ab initio designed antimicrobial peptides against gram-negative bacteria","volume":"12","author":"Bobde","year":"2021","journal-title":"Front Microbiol"},{"issue":"2","key":"10.1016\/j.biopha.2025.118007_bib110","doi-asserted-by":"crossref","DOI":"10.1093\/femsre\/fuab052","article-title":"Phage display and other peptide display technologies","volume":"46","author":"Jaroszewicz","year":"2022","journal-title":"FEMS Microbiol Rev."},{"issue":"1","key":"10.1016\/j.biopha.2025.118007_bib111","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12915-022-01304-4","article-title":"Optimization of the antimicrobial peptide Bac7 by deep mutational scanning","volume":"20","author":"Koch","year":"2022","journal-title":"BMC Biol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118007_bib112","first-page":"445","article-title":"Antimicrobial peptides therapy: an emerging alternative for treating drug-resistant bacteria","volume":"95","author":"Mba","year":"2022","journal-title":"Yale J. Biol. Med"},{"issue":"1","key":"10.1016\/j.biopha.2025.118007_bib113","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/cbdd.12478","article-title":"Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens","volume":"85","author":"Gill","year":"2015","journal-title":"Chem. Biol. Drug Des."},{"issue":"7","key":"10.1016\/j.biopha.2025.118007_bib114","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/08927014.2016.1194401","article-title":"Anti-biofilm properties of the antimicrobial peptide temporin 1Tb and its ability, in combination with EDTA, to eradicate Staphylococcus epidermidis biofilms on silicone catheters","volume":"32","author":"Maisetta","year":"2016","journal-title":"Biofouling"},{"issue":"5","key":"10.1016\/j.biopha.2025.118007_bib115","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3390\/ijms17050701","article-title":"Design and application of antimicrobial peptide conjugates","volume":"17","author":"Reinhardt","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"24","key":"10.1016\/j.biopha.2025.118007_bib116","doi-asserted-by":"crossref","first-page":"9779","DOI":"10.1021\/acs.jmedchem.5b01578","article-title":"Synthesis of tridecaptin-antibiotic conjugates with in vivo activity against Gram-negative bacteria","volume":"58","author":"Cochrane","year":"2015","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.biopha.2025.118007_bib117","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1021\/acs.molpharmaceut.5b00053","article-title":"Bacteria-targeting conjugates based on antimicrobial peptide for bacteria diagnosis and therapy","volume":"12","author":"Chen","year":"2015","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2025.118007_bib118","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1086\/491711","article-title":"Vancomycin resistance in Gram-positive cocci","volume":"42","author":"Courvalin","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2025.118007_bib119","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2147\/IDR.S160975","article-title":"Novel vancomycin-peptide conjugate as potent antibacterial agent against vancomycin-resistant Staphylococcus aureus","volume":"11","author":"Jelinkova","year":"2018","journal-title":"Infect. Drug Resist"},{"issue":"1-2","key":"10.1016\/j.biopha.2025.118007_bib120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.mce.2006.11.016","article-title":"Use of hecatechorionic gonadotropin beta conjugate in therapy of lutenizing hormone receptor expressing gonadal somatic cell tumors","volume":"269","author":"Rivero-Muller","year":"2007","journal-title":"Mol. Cell Endocrinol."},{"issue":"23","key":"10.1016\/j.biopha.2025.118007_bib121","doi-asserted-by":"crossref","first-page":"8823","DOI":"10.1002\/anie.202002727","article-title":"Vancomycin resistance is overcome by conjugation of polycationic peptides","volume":"59","author":"Umst\u00e4tter","year":"2020","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"9","key":"10.1016\/j.biopha.2025.118007_bib122","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/ki.2010.35","article-title":"Recent changes in vancomycin use in renal failure","volume":"77","author":"Vandecasteele","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.biopha.2025.118007_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128122","article-title":"Design, synthesis, and antibacterial evaluation of vancomycin-LPS binding peptide conjugates","volume":"45","author":"Shi","year":"2021","journal-title":"Bioorg. Med Chem. Lett."},{"issue":"5","key":"10.1016\/j.biopha.2025.118007_bib124","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/psc.2708","article-title":"Peptide IDR-1018: modulating the immune system and targeting bacterial biofilms to treat antibiotic-resistant bacterial infections","volume":"21","author":"Mansour","year":"2015","journal-title":"J. Pept. Sci."},{"issue":"22","key":"10.1016\/j.biopha.2025.118007_bib125","doi-asserted-by":"crossref","first-page":"16854","DOI":"10.1021\/acs.jmedchem.1c01712","article-title":"Multifunctional antibiotic-host defense peptide conjugate kills bacteria, eradicates biofilms, and modulates the innate immune response","volume":"64","author":"Etayash","year":"2021","journal-title":"J. Med Chem."},{"issue":"1","key":"10.1016\/j.biopha.2025.118007_bib126","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00140-17","article-title":"New mouse model for chronic infections by Gram-negative bacteria enabling the study of anti-infective efficacy and host-microbe interactions","volume":"8","author":"Pletzer","year":"2017","journal-title":"mBio"},{"issue":"9","key":"10.1016\/j.biopha.2025.118007_bib127","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s11094-021-02510-0","article-title":"Potential for the development of a new generation of aminoglycoside antibiotics","volume":"55","author":"Tevyashova","year":"2021","journal-title":"Pharm. Chem. J."},{"issue":"21","key":"10.1016\/j.biopha.2025.118007_bib128","doi-asserted-by":"crossref","first-page":"19047","DOI":"10.1021\/acsomega.3c02071","article-title":"Conjugates of aminoglycosides with stapled peptides as a way to target antibiotic-resistant bacteria","volume":"8","author":"Macyszyn","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.biopha.2025.118007_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2019.103871","article-title":"Study on the effects of different dimerization positions on biological activity of partial d-amino acid substitution analogues of Anoplin","volume":"139","author":"Zhong","year":"2020","journal-title":"Micro Pathog."},{"issue":"7","key":"10.1016\/j.biopha.2025.118007_bib130","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00775-018-1588-y","article-title":"Evaluation of a reducible disulfide linker for siderophore-mediated delivery of antibiotics","volume":"23","author":"Neumann","year":"2018","journal-title":"J. Biol. Inorg. Chem."},{"issue":"7","key":"10.1016\/j.biopha.2025.118007_bib131","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1039\/C7NP00020K","article-title":"Proline-rich antimicrobial peptides targeting protein synthesis","volume":"34","author":"Graf","year":"2017","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.biopha.2025.118007_bib132","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01660-16","article-title":"The mechanism of killing by the proline-rich peptide Bac7(1\u201335) against clinical strains of Pseudomonas aeruginosa differs from that against other gram-negative bacteria","volume":"61","author":"Runti","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.biopha.2025.118007_bib133","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1021\/acs.bioconjchem.2c00467","article-title":"Designing new hybrid antibiotics: proline-rich antimicrobial peptides conjugated to the aminoglycoside tobramycin","volume":"34","author":"Gambato","year":"2023","journal-title":"Bioconjug Chem."},{"issue":"4","key":"10.1016\/j.biopha.2025.118007_bib134","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jcf.2015.07.012","article-title":"The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: a randomised comparison","volume":"15","author":"Prayle","year":"2016","journal-title":"J. Cyst. Fibros."},{"issue":"34","key":"10.1016\/j.biopha.2025.118007_bib135","doi-asserted-by":"crossref","first-page":"10945","DOI":"10.1021\/jacs.6b04831","article-title":"Dual targeting of intracellular pathogenic bacteria with a cleavable conjugate of kanamycin and an antibacterial cell-penetrating peptide","volume":"138","author":"Brezden","year":"2016","journal-title":"J. Am. Chem. Soc."},{"issue":"37","key":"10.1016\/j.biopha.2025.118007_bib136","doi-asserted-by":"crossref","first-page":"9664","DOI":"10.1002\/anie.201302693","article-title":"Targeting intracellular pathogenic bacteria with unnatural proline-rich peptides: coupling antibacterial activity with macrophage penetration","volume":"52","author":"Kuriakose","year":"2013","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.biopha.2025.118007_bib137","doi-asserted-by":"crossref","DOI":"10.1002\/pep2.24059","article-title":"Covalent conjugation of cationic antimicrobial peptides with a \u03b2-lactam antibiotic core","volume":"110","author":"Li","year":"2018","journal-title":"Pept. Sci."},{"issue":"24","key":"10.1016\/j.biopha.2025.118007_bib138","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.2174\/1568026618666181022140348","article-title":"Antimicrobial activity of different antimicrobial peptides (AMPs) against clinical methicillin-resistant Staphylococcus aureus (MRSA)","volume":"18","author":"Ciandrini","year":"2018","journal-title":"Curr. Top. Med. Chem."},{"issue":"11","key":"10.1016\/j.biopha.2025.118007_bib139","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1021\/acsinfecdis.2c00406","article-title":"Development of antimicrobial peptide-antibiotic conjugates to improve the outer membrane permeability of antibiotics against gram-negative bacteria","volume":"8","author":"Yamauchi","year":"2022","journal-title":"ACS Infect. Dis."},{"issue":"11","key":"10.1016\/j.biopha.2025.118007_bib140","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.3390\/antibiotics11111636","article-title":"Antimicrobial and cell-penetrating peptides: understanding penetration for the design of novel conjugate antibiotics","volume":"11","author":"Hadjicharalambous","year":"2022","journal-title":"Antibiot. (Basel)"},{"issue":"10","key":"10.1016\/j.biopha.2025.118007_bib141","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1007\/s13238-017-0495-2","article-title":"Mechanism of actions of Oncocin, a proline-rich antimicrobial peptide, in early elongation revealed by single-molecule FRET","volume":"9","author":"Peng","year":"2018","journal-title":"Protein Cell"},{"issue":"2","key":"10.1016\/j.biopha.2025.118007_bib142","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1517\/13543784.10.2.213","article-title":"Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infections","volume":"10","author":"Blondeau","year":"2001","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"4","key":"10.1016\/j.biopha.2025.118007_bib143","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1039\/C9MD00051H","article-title":"Polybasic peptide-levofloxacin conjugates potentiate fluoroquinolones and other classes of antibiotics against multidrug-resistant Gram-negative bacteria","volume":"10","author":"Berry","year":"2019","journal-title":"Med. Chem. Comm."},{"issue":"7654","key":"10.1016\/j.biopha.2025.118007_bib144","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nature22308","article-title":"Predictive compound accumulation rules yield a broad-spectrum antibiotic","volume":"545","author":"Richter","year":"2017","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.biopha.2025.118007_bib145","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.3390\/ijms21134696","article-title":"Conjugates of ciprofloxacin and levofloxacin with cell-penetrating peptide exhibit antifungal activity and mammalian cytotoxicity","volume":"21","author":"Ptaszy\u0144ska","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118007_bib146","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ijantimicag.2010.08.020","article-title":"Fungicidal activity of human lactoferrin-derived peptides based on the antimicrobial \u03b1\u03b2 region","volume":"37","author":"Kondori","year":"2011","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.biopha.2025.118007_bib147","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.drup.2016.04.002","article-title":"Mechanisms and consequences of bacterial resistance to antimicrobial peptides","volume":"26","author":"Andersson","year":"2016","journal-title":"Drug Resist Updat"},{"issue":"2","key":"10.1016\/j.biopha.2025.118007_bib148","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3109\/1040841X.2012.699025","article-title":"Bacterial resistance to cationic antimicrobial peptides","volume":"39","author":"Anaya-L\u00f3pez","year":"2013","journal-title":"Crit. Rev. Microbiol"},{"key":"10.1016\/j.biopha.2025.118007_bib149","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrmicro1441","article-title":"The co-evolution of host cationic antimicrobial peptides and microbial resistance","volume":"4","author":"Peschel","year":"2006","journal-title":"Nat. Rev. Microbiol"},{"key":"10.1016\/j.biopha.2025.118007_bib150","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.tim.2021.03.007","article-title":"Evolutionary constraints on the acquisition of antimicrobial peptide resistance in bacterial pathogens","volume":"29","author":"Jangir","year":"2021","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.biopha.2025.118007_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105276","article-title":"The revitalization of antimicrobial peptides in the resistance era","volume":"163","author":"Liu","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2025.118007_bib152","doi-asserted-by":"crossref","unstructured":"Kintses B., M\u00e9hi O., Ari E., Sz\u00e1mel M., Gy\u00f6rkei \u00c1., Jangir P.K., et al. Phylogenetic barriers to horizontal transfer of antimicrobial peptide resistance genes in the human gut microbiota. Nat. Microbiol. 201;4:447\u2013458.","DOI":"10.1038\/s41564-018-0313-5"},{"key":"10.1016\/j.biopha.2025.118007_bib153","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.616979","article-title":"Review: lessons learned from clinical trials using antimicrobial peptides (AMPs)","volume":"12","author":"Dijksteel","year":"2021","journal-title":"Front Microbiol"},{"issue":"48","key":"10.1016\/j.biopha.2025.118007_bib154","doi-asserted-by":"crossref","first-page":"14130","DOI":"10.1021\/bi035643g","article-title":"Structure-based design of an indolicidin peptide analogue with increased protease stability","volume":"42","author":"Rozek","year":"2003","journal-title":"Biochemistry"},{"issue":"47","key":"10.1016\/j.biopha.2025.118007_bib155","doi-asserted-by":"crossref","first-page":"46590","DOI":"10.1074\/jbc.M308615200","article-title":"Synthetic peptides in the form of dendrimers become resistant to protease activity","volume":"278","author":"Bracci","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.biopha.2025.118007_bib156","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1096\/fj.09-145474","article-title":"A novel tetrabranched antimicrobial peptide that neutralizes bacterial lipopolysaccharide and prevents septic shock in vivo","volume":"24","author":"Pini","year":"2010","journal-title":"FASEB J."},{"issue":"10","key":"10.1016\/j.biopha.2025.118007_bib157","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046259","article-title":"Isomerization of an antimicrobial peptide broadens antimicrobial spectrum to gram-positive bacterial pathogens","volume":"7","author":"Falciani","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biopha.2025.118007_bib158","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-69995-9","article-title":"Correlation between hemolytic activity, cytotoxicity and systemic in vivo toxicity of synthetic antimicrobial peptides","volume":"10","author":"Greco","year":"2020","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2025.118007_bib159","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.biochi.2011.08.011","article-title":"Antitumor effects and cell selectivity of temporin-1CEa, an antimicrobial peptide from the skin secretions of the Chinese brown frog (Rana chensinensis)","volume":"94","author":"Wang","year":"2012","journal-title":"Biochimie"},{"issue":"12","key":"10.1016\/j.biopha.2025.118007_bib160","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1021\/acsinfecdis.7b00123","article-title":"structure-activity and -toxicity relationships of the antimicrobial peptide Tachyplesin-1","volume":"3","author":"Edwards","year":"2017","journal-title":"ACS Infect. Dis."},{"issue":"2","key":"10.1016\/j.biopha.2025.118007_bib161","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/0005-2736(73)90143-0","article-title":"The asymmetric distribution of phospholipids in the human red cell membrane. A combined study using phospholipases and freeze-etch electron microscopy","volume":"323","author":"Verkleij","year":"1973","journal-title":"Biochem Biophys. Acta"},{"issue":"8","key":"10.1016\/j.biopha.2025.118007_bib162","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.bbamem.2008.09.013","article-title":"Control of cell selectivity of antimicrobial peptides","volume":"1788","author":"Matsuzaki","year":"2009","journal-title":"Biochem Biophys. Acta"},{"issue":"34","key":"10.1016\/j.biopha.2025.118007_bib163","doi-asserted-by":"crossref","first-page":"10723","DOI":"10.1021\/bi0256983","article-title":"Position-dependent hydrophobicity of the antimicrobial magainin peptide affects the mode of peptide-lipid interactions and selective toxicity","volume":"41","author":"Tachi","year":"2002","journal-title":"Biochemistry"},{"issue":"6","key":"10.1016\/j.biopha.2025.118007_bib164","first-page":"1090","article-title":"Cell selectivity of an antimicrobial peptide melittin diastereomer with D-amino acid in the leucine zipper sequence","volume":"40","author":"Zhu","year":"2007","journal-title":"J. Biochem Mol. Biol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118007_bib165","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/psc.858","article-title":"Characterization of the branched antimicrobial peptide M6 by analyzing its mechanism of action and in vivo toxicity","volume":"13","author":"Pini","year":"2007","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.biopha.2025.118007_bib166","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.bsheal.2022.02.003","article-title":"Biosynthesis, bioactivity, biosafety and applications of antimicrobial peptides for human health","volume":"4","author":"Wei","year":"2022","journal-title":"Biosaf. Health"},{"issue":"11","key":"10.1016\/j.biopha.2025.118007_bib167","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1007\/s12272-013-0112-8","article-title":"Design of potent, non-toxic anticancer peptides based on the structure of the antimicrobial peptide, temporin-1CEa","volume":"36","author":"Yang","year":"2013","journal-title":"Arch. Pharm. Res"},{"issue":"33","key":"10.1016\/j.biopha.2025.118007_bib168","doi-asserted-by":"crossref","first-page":"17989","DOI":"10.1002\/anie.202104921","article-title":"Selective bacterial targeting and infection-triggered release of antibiotic colistin conjugates","volume":"60","author":"Tegge","year":"2021","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"1","key":"10.1016\/j.biopha.2025.118007_bib169","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12931-019-1145-4","article-title":"Neutrophil elastase as a biomarker for bacterial infection in COPD","volume":"20","author":"Thulborn","year":"2019","journal-title":"Respir. Res."},{"key":"10.1016\/j.biopha.2025.118007_bib170","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.actbio.2016.09.041","article-title":"Gold-nanoparticles coated with the antimicrobial peptide esculentin-1a(1-21)NH2 as a reliable strategy for antipseudomonal drugs","volume":"47","author":"Casciaro","year":"2017","journal-title":"Acta Biomater."},{"issue":"1","key":"10.1016\/j.biopha.2025.118007_bib171","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/pharmaceutics15010003","article-title":"Inhalable polymeric nanoparticles for pulmonary delivery of antimicrobial peptide SET-M33: antibacterial activity and toxicity in vitro and in vivo","volume":"15","author":"Cresti","year":"2022","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.biopha.2025.118007_bib172","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1039\/b906679a","article-title":"Chemistry and biology of siderophores","volume":"27","author":"Hider","year":"2010","journal-title":"Nat. Prod. Rep."},{"issue":"11","key":"10.1016\/j.biopha.2025.118007_bib173","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.15252\/embr.201540558","article-title":"The iron age of host-microbe interactions","volume":"16","author":"Soares","year":"2015","journal-title":"EMBO Rep."},{"issue":"6","key":"10.1016\/j.biopha.2025.118007_bib174","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1039\/C4MT00333K","article-title":"Diverging roles of bacterial siderophores during infection","volume":"7","author":"Holden","year":"2015","journal-title":"Metallomics"},{"issue":"4","key":"10.1016\/j.biopha.2025.118007_bib175","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10534-009-9219-2","article-title":"Siderophores as drug delivery agents: application of the \"Trojan Horse\" strategy","volume":"22","author":"M\u00f6llmann","year":"2009","journal-title":"Biometals"},{"issue":"2","key":"10.1016\/j.biopha.2025.118007_bib176","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/CMR.6.2.137","article-title":"Role of iron in regulation of virulence genes","volume":"6","author":"Litwin","year":"1993","journal-title":"Clin. Microbiol Rev."},{"key":"10.1016\/j.biopha.2025.118007_bib177","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/1471-2180-13-174","article-title":"Inhibiting biofilm formation by Klebsiella pneumoniae B5055 using an iron antagonizing molecule and a bacteriophage","volume":"13","author":"Chhibber","year":"2013","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.biopha.2025.118007_bib178","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.micres.2017.10.012","article-title":"Synthesis, nature and utility of universal iron chelator - siderophore: a review","volume":"212-213","author":"Khan","year":"2018","journal-title":"Microbiol Res"},{"issue":"4","key":"10.1016\/j.biopha.2025.118007_bib179","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10534-010-9361-x","article-title":"Siderophore uptake in bacteria and the battle for iron with the host; a bird's eye view","volume":"23","author":"Chu","year":"2010","journal-title":"Biometals"},{"issue":"4","key":"10.1016\/j.biopha.2025.118007_bib180","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1042\/bst0300691","article-title":"Microbial siderophore-mediated transport","volume":"30","author":"Winkelmann","year":"2002","journal-title":"Biochem Soc. Trans."},{"key":"10.1016\/j.biopha.2025.118007_bib181","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/B978-0-12-394390-3.00002-1","article-title":"Structure, function and binding selectivity and stereoselectivity of siderophore-iron outer membrane transporters","volume":"69","author":"Schalk","year":"2012","journal-title":"Curr. Top. Membr."},{"issue":"10","key":"10.1016\/j.biopha.2025.118007_bib182","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026734","article-title":"Hypervirulent K. pneumoniae secretes more and more active iron-acquisition molecules than \"classical\" K. pneumoniae thereby enhancing its virulence","volume":"6","author":"Russo","year":"2011","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.biopha.2025.118007_bib183","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.4049\/jimmunol.1700261","article-title":"Bacterial siderophores hijack neutrophil functions","volume":"198","author":"Saha","year":"2017","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118007_bib184","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1128\/IAI.06279-11","article-title":"Role of acinetobactin-mediated iron acquisition functions in the interaction of Acinetobacter baumannii strain ATCC 19606T with human lung epithelial cells, Galleria mellonella caterpillars, and mice","volume":"80","author":"Gaddy","year":"2012","journal-title":"Infect. Immun."},{"issue":"2","key":"10.1016\/j.biopha.2025.118007_bib185","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijmm.2008.06.008","article-title":"Role of siderophores in cystic fibrosis pathogenesis: foes or friends?","volume":"299","author":"Mossialos","year":"2009","journal-title":"Int J. Med. Microbiol"},{"issue":"22","key":"10.1016\/j.biopha.2025.118007_bib186","doi-asserted-by":"crossref","first-page":"6751","DOI":"10.1007\/s00253-023-12742-7","article-title":"Opportunities and challenges of microbial siderophores in the medical field","volume":"107","author":"Passari","year":"2023","journal-title":"Appl. Microbiol Biotechnol."},{"key":"10.1016\/j.biopha.2025.118007_bib187","first-page":"151","article-title":"Sideromycins as pathogen-targeted antibiotics","volume":"II","author":"Wencewicz","year":"2018"},{"key":"10.1016\/j.biopha.2025.118007_bib188","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1038\/s41467-018-05821-1","article-title":"Total synthesis and antimicrobial evaluation of natural albomycins against clinical pathogens","volume":"9","author":"Lin","year":"2018","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.biopha.2025.118007_bib189","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1021\/jm00107a013","article-title":"Synthesis and siderophore activity of albomycin-like peptides derived from N5-acetyl-N5-hydroxy-L-ornithine","volume":"34","author":"Dolence","year":"1991","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2025.118007_bib190","doi-asserted-by":"crossref","first-page":"230","DOI":"10.7164\/antibiotics.39.230","article-title":"Semisynthetic beta-lactam antibiotics. Synthesis and antibacterial activity of new ureidopenicillin derivatives having catechol moieties","volume":"39","author":"Ohi","year":"1986","journal-title":"J. Antibiot."},{"issue":"10","key":"10.1016\/j.biopha.2025.118007_bib191","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1128\/AAC.36.10.2166","article-title":"Modes of action and inhibitory activities of new siderophore-beta-lactam conjugates that use specific iron uptake pathways for entry into bacteria","volume":"36","author":"Brochu","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.biopha.2025.118007_bib192","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1128\/AAC.01525-09","article-title":"In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multi-resistant Gram-negative bacilli","volume":"54","author":"Page","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.biopha.2025.118007_bib193","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/cpdd.637","article-title":"Pharmacokinetics, safety, and tolerability evaluation of single and multiple doses of GSK3342830 in healthy volunteers","volume":"8","author":"Tenero","year":"2019","journal-title":"Clin. Pharm. Drug Dev."},{"issue":"11","key":"10.1016\/j.biopha.2025.118007_bib194","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1007\/s00204-017-1994-x","article-title":"Mechanisms of hepatotoxicity associated with the monocyclic \u03b2-lactam antibiotic BAL30072","volume":"91","author":"Paech","year":"2017","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.biopha.2025.118007_bib195","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1021\/acsmedchemlett.5b00026","article-title":"SAR and structural analysis of siderophore-conjugated monocarbam inhibitors of Pseudomonas aeruginosa PBP3","volume":"6","author":"Murphy-Benenato","year":"2015","journal-title":"ACS Med Chem. Lett."},{"issue":"4","key":"10.1016\/j.biopha.2025.118007_bib196","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1128\/AAC.01370-10","article-title":"In vitro and in vivo properties of BAL30376, a \u03b2-lactam and dual beta-lactamase inhibitor combination with enhanced activity against Gram-negative bacilli that express multiple \u03b2-lactamases","volume":"55","author":"Page","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.biopha.2025.118007_bib197","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01454-17","article-title":"In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria","volume":"62","author":"Ito","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.biopha.2025.118007_bib198","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ijantimicag.2018.11.007","article-title":"In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015","volume":"53","author":"Karlowsky","year":"2019","journal-title":"Int J. Antimicrob. Agents"},{"key":"10.1016\/j.biopha.2025.118007_bib199","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","article-title":"Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli","volume":"79","author":"Zhanel","year":"2019","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.biopha.2025.118007_bib200","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s10096-017-3063-z","article-title":"Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens","volume":"36","author":"Dobias","year":"2017","journal-title":"Eur. J. Clin. Microbiol Infect. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2025.118007_bib201","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2020.115012","article-title":"In vitro activity of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacilli isolated from patients in Canadian intensive care units","volume":"97","author":"Golden","year":"2020","journal-title":"Diagn. Microbiol Infect. Dis."},{"key":"10.1016\/j.biopha.2025.118007_bib202","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s40261-020-00955-x","article-title":"Cefiderocol, a new siderophore cephalosporin for the treatment of complicated urinary tract infections caused by multidrug-resistant pathogens: preclinical and clinical pharmacokinetics, pharmacodynamics, efficacy and safety","volume":"40","author":"Lee","year":"2020","journal-title":"Clin. Drug Invest."},{"issue":"12","key":"10.1016\/j.biopha.2025.118007_bib203","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.biopha.2025.118007_bib204","unstructured":"Fetroja (Cefiderocol) [prescribing information]. Osaka JSC, Ltd. 2020."},{"issue":"2","key":"10.1016\/j.biopha.2025.118007_bib205","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s40121-022-00598-9","article-title":"Outcomes with cefiderocol treatment in patients with bacteraemia enrolled into prospective phase 2 and phase 3 randomized clinical studies","volume":"11","author":"Paterson","year":"2022","journal-title":"Infect. Dis. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2025.118007_bib206","article-title":"Cefiderocol (Fetroja) as a treatment for hospital-acquired pneumonia","volume":"16","author":"Plaisance","year":"2024","journal-title":"Cureus"},{"issue":"11","key":"10.1016\/j.biopha.2025.118007_bib207","doi-asserted-by":"crossref","first-page":"12478","DOI":"10.3390\/molecules171112478","article-title":"Development of new drugs for an old target - the penicillin binding proteins","volume":"17","author":"Zervosen","year":"2012","journal-title":"Molecules"},{"issue":"9","key":"10.1016\/j.biopha.2025.118007_bib208","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1021\/jm500219c","article-title":"Siderophore receptor-mediated uptake of lactivicin analogues in gram-negative bacteria","volume":"57","author":"Starr","year":"2014","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.biopha.2025.118007_bib209","doi-asserted-by":"crossref","first-page":"5990","DOI":"10.1021\/acs.jmedchem.0c00255","article-title":"A \u03b3-lactam siderophore antibiotic effective against multidrug-resistant gram-negative bacilli","volume":"63","author":"Goldberg","year":"2020","journal-title":"J. Med Chem."},{"issue":"7","key":"10.1016\/j.biopha.2025.118007_bib210","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1086\/383472","article-title":"Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens","volume":"38","author":"Carpenter","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2025.118007_bib211","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1021\/acsinfecdis.8b00150","article-title":"Siderophore conjugates of daptomycin are potent inhibitors of carbapenem resistant strains of Acinetobacter baumannii","volume":"4","author":"Ghosh","year":"2018","journal-title":"ACS Infect. Dis."},{"issue":"20","key":"10.1016\/j.biopha.2025.118007_bib212","doi-asserted-by":"crossref","first-page":"15440","DOI":"10.1021\/acs.jmedchem.1c01482","article-title":"Antibiotic conjugates with an artificial MECAM-based siderophore are potent agents against Gram-positive and Gram-negative bacterial pathogens","volume":"64","author":"Pinkert","year":"2021","journal-title":"J. Med Chem."},{"issue":"36","key":"10.1016\/j.biopha.2025.118007_bib213","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202204139","article-title":"Drug repurposing by siderophore conjugation: synthesis and biological evaluation of siderophore-methotrexate conjugates as antibiotics","volume":"61","author":"Zhao","year":"2022","journal-title":"Angew. Chem. Int Ed. Engl."},{"issue":"28","key":"10.1016\/j.biopha.2025.118007_bib214","doi-asserted-by":"crossref","first-page":"12756","DOI":"10.1021\/jacs.2c03324","article-title":"Heavy-Metal Trojan Horse: Enterobactin-directed delivery of platinum(IV) prodrugs to Escherichia coli","volume":"144","author":"Guo","year":"2022","journal-title":"J. Am. Chem. Soc."},{"issue":"9","key":"10.1016\/j.biopha.2025.118007_bib215","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1021\/acs.jmedchem.8b00218","article-title":"A synthetic dual drug sideromycin induces Gram-negative bacteria to commit suicide with a Gram-positive antibiotic","volume":"61","author":"Liu","year":"2018","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2025.118007_bib216","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10534-015-9830-3","article-title":"Siderophore-fluoroquinolone conjugates containing potential reduction-triggered linkers for drug release: synthesis and antibacterial activity","volume":"28","author":"Ji","year":"2015","journal-title":"Biometals"},{"issue":"3","key":"10.1016\/j.biopha.2025.118007_bib217","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000494627","article-title":"The iron tug-of-war between bacterial siderophores and innate immunity","volume":"11","author":"Golonka","year":"2019","journal-title":"J. Innate Immun."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222500201X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222500201X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:05:58Z","timestamp":1781823958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222500201X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":217,"alternative-id":["S075333222500201X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118007","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibiotic conjugates: Using molecular Trojan Horses to overcome drug resistance","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118007"}}